Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability.

Abstract

Background: Lithium is a well-established treatment for bipolar disorders and has been shown to be neuroprotective, and thus low doses might be useful for the treatment of childhood brain injury and neurological sequelae. However, pharmacokinetic (PK) data in children are limited. This study was to investigate the PKs after oral administration of low-dose lithium carbonate in young children with intellectual disability. Methods: Fifty-two children with intellectual disability aged 4-10 years old were enrolled. A series of blood samples were collected after a single-dose administration of lithium carbonate. The serum lithium concentration was measured using a validated ion chromatography assay, and the PK concentration data were modeled using a nonlinear mixed effect model in the NONMEM program. Results: The lithium concentration over time was adequately described by a two-compartment disposition, with a transient absorption and first-order elimination process. The inclusion of body weight as an allometric factor significantly improved the model fit, but age and gender were not associated with the PKs of lithium. The clearance, central volume, inter-compartmental clearance, and peripheral volume estimates from the final population PK model were 0.98 L/h, 13.1 L, 0.84 L/h, and 8.2 L for children with a body weight of 20 kg. The model evaluation suggested that there is no obvious discrepancy between the observations and predictions in the proposed model. A visual predictive check demonstrated the good predictive performance of the final model. Conclusions: The lithium PK properties in young children were similar to those in older children and adults. The proposed model can be used for further PK/PD analysis to optimize the dosage regimen of lithium in children.

• Authors: Junying Yuan, Bohao Zhang, Yiran Xu, Xiaoli Zhang, Juan Song, Wenhao Zhou, Kai Hu, Dengna Zhu, Lirong Zhang, Fengmin Shao, Shusheng Zhang, Junjie Ding, Changlian Zhu
• Journal: Frontiers in pharmacology (Front Pharmacol) Vol. 12 Pg. 650298 ( 2021) ISSN: 1663-9812 [Print] Switzerland
• PMID: 33935755 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Yuan, Zhang, Xu, Zhang, Song, Zhou, Hu, Zhu, Zhang, Shao, Zhang, Ding and Zhu.